- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04306900
TTX-030 in Combination With Immunotherapy and/or Chemotherapy in Subjects With Advanced Cancers
Phase 1/1b Study to Evaluate the Safety and Activity of TTX-030 (Anti-CD39) in Combination With Pembrolizumab or Budigalimab and/or Chemotherapy in Subjects With Advanced Solid Tumors
This is a phase 1/1b study of TTX-030 in combination therapy, an antibody that inhibits CD39 enzymatic activity, leading to accumulation of pro-inflammatory adenosine triphosphate (ATP) and reduction of immunosuppressive adenosine, which may change the tumor microenvironment and promote anti-tumor immune response.
This trial will study the safety, tolerability, pharmacokinetics, pharmacodynamics and anti-tumor activity of TTX-030 in combination with immunotherapy and/or standard chemotherapies.
Study Overview
Status
Conditions
Intervention / Treatment
- Combination product: TTX-030, budigalimab and mFOLFOX6
- Combination product: TTX-030, budigalimab and docetaxel
- Combination product: TTX-030 and mFOLFOX6
- Combination product: TTX-030 and pembrolizumab
- Combination product: TTX-030 and budigalimab
- Combination product: TTX-030, budigalimab, nab-paclitaxel and gemcitabine
- Combination product: TTX-030, nab-paclitaxel and gemcitabine
- Combination product: Budigalimab and mFOLFOX6
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Busan
-
Seogu, Busan, Korea, Republic of, 49201
- National Cancer Center
-
-
Goyang-si, Gyeonggi-do
-
Ilsandong-gu, Goyang-si, Gyeonggi-do, Korea, Republic of, 10408
- National Cancer Center
-
-
Kyunggi-do
-
Seongnam-si Bundan-gu, Kyunggi-do, Korea, Republic of, 13620
- Seoul National University
-
-
Seoul
-
Gangnam-gu, Seoul, Korea, Republic of, 06351
- Samsung Medical Center
-
Seodaemun-gu, Seoul, Korea, Republic of, 03722
- Severance Hospital Yonsei University
-
Songpa-gu, Seoul, Korea, Republic of, 05505
- Asan Medical Center
-
-
-
-
Arizona
-
Scottsdale, Arizona, United States, 85258
- HonorHealth Research Institute
-
-
California
-
Duarte, California, United States, 91010
- City of Hope Medical Center Clinical Trials Office
-
Los Angeles, California, United States, 90048
- Cedars-Sinai Medical Center
-
Los Angeles, California, United States, 90007
- University of Southern California
-
Los Angeles, California, United States, 90404
- UCLA Hematology/Oncology
-
Orange, California, United States, 92868
- Chao Family Comprehensive CC, UCI
-
Sacramento, California, United States, 95817
- UC Davis Comprehensive Cancer Center
-
-
Florida
-
Miami, Florida, United States, 33136
- Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine
-
Ocala, Florida, United States, 34474
- Ocala Oncology Center PL
-
Orlando, Florida, United States, 32835
- Orlando Health UF Health Cancer Center
-
-
Georgia
-
Columbus, Georgia, United States, 31904
- IACT Health - John B. Amos Cancer Center
-
-
Illinois
-
Chicago, Illinois, United States, 60637
- University of Chicago Medical Center
-
-
Kentucky
-
Louisville, Kentucky, United States, 40202
- Norton Cancer Institute
-
-
Louisiana
-
New Orleans, Louisiana, United States, 70121
- Ochsner Medical Center
-
-
Nebraska
-
Omaha, Nebraska, United States, 68130
- Nebraska Cancer Center Oncology Hematology West P.C.
-
-
New York
-
Bronx, New York, United States, 10461
- Montefiore Medical Center
-
-
Ohio
-
Cleveland, Ohio, United States, 44122
- University Hospitals Cleveland Medical Center
-
Toledo, Ohio, United States, 43614
- University of Toledo
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, United States, 15232
- UPMC Hillman Cancer Center
-
-
South Carolina
-
Greenville, South Carolina, United States, 29605
- Prisma-Health Cancer Institute
-
-
Tennessee
-
Germantown, Tennessee, United States, 38138
- West Cancer Center and Research Institute
-
Nashville, Tennessee, United States, 37203
- Sarah Cannon Research Institute
-
-
Texas
-
San Antonio, Texas, United States, 78229
- Next Oncology
-
-
Utah
-
Salt Lake City, Utah, United States, 84112
- Hunstman Cancer Intitute
-
-
Virginia
-
Fairfax, Virginia, United States, 22031
- Virginia Cancer Specialists
-
-
Wisconsin
-
Milwaukee, Wisconsin, United States, 53226
- Froedtert Hospital & Medical College of Wisconsin
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Abbreviated Inclusion Criteria:
- Age 18 years or older, is willing and able to provide informed consent
- Histologically confirmed diagnosis of unresectable or metastatic solid tumor malignancy in selected tumor types
- Life expectancy > 12 weeks
- ECOG performance status of 0-1
Abbreviated Exclusion Criteria:
- History of allergy or hypersensitivity to study treatment components. Patients with a history of severe hypersensitivity reaction to any monoclonal antibody.
- Use of investigational agent within 28 days prior to the first dose of study treatment and throughout the study
- Receiving high-dose systemic steroid therapy or any other form of immunosuppressive therapy
- History of severe autoimmune disease
- Uncontrolled intercurrent illness or other active malignancy requiring ongoing treatment
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Combo 1
TTX-030 plus budigalimab plus mFOLFOX6
|
Dose and schedule per protocol
|
Experimental: Combo 2
TTX-030 plus budigalimab plus docetaxel
|
Dose and schedule per protocol
|
Experimental: Combo 3
TTX-030 plus mFOLFOX6
|
Dose and schedule per protocol
|
Experimental: Combo 4
TTX-030 plus pembrolizumab
|
Dose and schedule per protocol
|
Experimental: Combo 5
TTX-030 plus budigalimab (selected tumors evaluated in expansion)
|
Dose and schedule per protocol
|
Experimental: Combo 6
TTX-030 plus budigalimab plus nab-paclitaxel + gemcitabine
|
Dose and schedule per protocol
|
Experimental: Combo 7
TTX-030 plus nab-paclitaxel + gemcitabine
|
Dose and schedule per protocol
|
Experimental: Combo 8
Budigalimab plus mFOLFOX6
|
Dose and schedule per protocol
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Adverse Events
Time Frame: Through study completion, an average of 1 year
|
Number of study subjects experiencing adverse events (AEs), dose-limiting toxicities, and serious adverse events (SAEs).
Safety profile will be assessed through laboratory evaluations, vital signs, and physical examinations.
|
Through study completion, an average of 1 year
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Objective Response Rate (ORR)
Time Frame: Through study completion, an average of 1 year
|
ORR is defined as the proportion of subjects with CR or PR
|
Through study completion, an average of 1 year
|
Duration of response (DoR)
Time Frame: Through study completion, an average of 1 year
|
DoR will be defined as the duration from the first documentation of objective response to the first documented disease progression or death due to any cause, whichever occurs first.
|
Through study completion, an average of 1 year
|
Disease control rate (DCR)
Time Frame: Through study completion, an average of 1 year
|
DCR is defined as the proportion of subjects with CR, PR, or SD
|
Through study completion, an average of 1 year
|
Progression-free survival (PFS)
Time Frame: Through study completion, an average of 1 year
|
PFS is measured from documentation of progression or death from any cause, whichever occurs first
|
Through study completion, an average of 1 year
|
Pharmacokinetics (PK)
Time Frame: Cycles 1-4 (each cycle is 21-28 days)
|
Serum concentrations of TTX-030 will be tabulated
|
Cycles 1-4 (each cycle is 21-28 days)
|
Collaborators and Investigators
Sponsor
Collaborators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
- Gemcitabine
- Docetaxel
- Cancer
- Colorectal cancer
- Bladder cancer
- Non-small cell lung cancer
- Pembrolizumab
- Keytruda
- Pancreatic cancer
- Combination Therapy
- Advanced Solid Tumor
- Metastatic Solid Tumor
- Nab-paclitaxel
- ABBV-181
- Budigalimab
- Gastric (gastroesophageal cancer)
- CD39
- Adenosine Pathway
- Immunotherapy Immuno-oncology
- PD-1 Checkpoint Inhibitor
- TTX-030
- Urothelial cell cancer
Additional Relevant MeSH Terms
- Neoplasms
- Molecular Mechanisms of Pharmacological Action
- Antimetabolites, Antineoplastic
- Antimetabolites
- Antineoplastic Agents
- Tubulin Modulators
- Antimitotic Agents
- Mitosis Modulators
- Antineoplastic Agents, Phytogenic
- Antineoplastic Agents, Immunological
- Immune Checkpoint Inhibitors
- Docetaxel
- Paclitaxel
- Pembrolizumab
- Albumin-Bound Paclitaxel
- Gemcitabine
Other Study ID Numbers
- TTX-030-002
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Solid Tumor, Adult
-
Memorial Sloan Kettering Cancer CenterRecruitingSolid Tumor | Solid Tumor, Adult | Solid Tumor, Unspecified, AdultUnited States
-
Memorial Sloan Kettering Cancer CenterLincoln Medical and Mental Health CenterRecruitingSolid Tumor | Solid Tumor, Adult | Solid Tumor, Unspecified, AdultUnited States, Puerto Rico
-
Memorial Sloan Kettering Cancer CenterLincoln Medical and Mental Health CenterRecruitingSolid Tumor | Solid Tumor, Adult | Solid Tumor, Unspecified, AdultUnited States, Puerto Rico
-
Partner Therapeutics, Inc.WithdrawnSolid Tumor | Solid Tumor, AdultUnited States
-
Shenzhen Ionova Life Sciences Co., Ltd.Merck Sharp & Dohme LLCRecruitingCancer | Solid Tumor, Adult | Solid Carcinoma | Solid Tumor, Unspecified, Adult | Cancer Metastatic | Tumor, SolidUnited States
-
Invitae CorporationRecruitingCancer | Solid Tumor | Solid Tumor, AdultUnited States
-
Sairopa B.V.RecruitingMetastatic Solid Tumor | Solid Tumor, Adult | Refractory CancerUnited States, Moldova, Republic of
-
Institut CurieRecruitingChemotherapy Effect | Solid Tumor, Adult | Solid Tumor, ChildhoodFrance
-
New York Stem Cell Foundation Research InstituteStevens Institute of TechnologyRecruiting
-
JemincareNot yet recruiting
Clinical Trials on TTX-030, budigalimab and mFOLFOX6
-
Trishula Therapeutics, Inc.AbbVieRecruitingPancreatic CancerUnited States
-
Merck Sharp & Dohme LLCCompletedHIV Infections | Candidiasis, EsophagealUnited States
-
Trishula Therapeutics, Inc.CompletedLymphoma | Solid TumorUnited States
-
TransCode TherapeuticsRecruitingAdvanced Solid TumorUnited States
-
AbbVieCompletedHIV Infection | HIV-1 | Human Immunodeficiency Virus (HIV)United States, Australia, Canada, Puerto Rico
-
AbbVieActive, not recruitingAdvanced Solid Tumors CancerUnited States, Australia, Canada, France, Japan, Korea, Republic of, Spain
-
AbbVieRecruitingHuman Immuno-deficiency Virus (HIV) DiseaseUnited States, Puerto Rico, Japan, Spain, Germany
-
Sixth Affiliated Hospital, Sun Yat-sen UniversityRecruitingColorectal Cancer | Adjuvant ChemotherapyChina
-
Rui-hua Xu, MD, PhDNot yet recruitingAdvanced Pancreatic CancerChina
-
AbbVieRecruitingAdvanced Solid Tumors CancerUnited States, Australia, Belgium, Israel, Japan, Korea, Republic of, Puerto Rico, Spain, Taiwan, Canada, France